Use of AI in Basic Science - From Translation to Treatment - (Part 2)-Use of AI in Basic Research: Translation to Transition (Pt 2)

Video Transcription

Video Summary

In this webinar, Dr. Katie Wack, Senior VP of Clinical Science at PATH AI, discusses the application of AI-powered digital pathology in addressing challenges of metabolic-associated steatohepatitis (MASH), a severe fatty liver disease. PATH AI’s mission is to improve patient outcomes by developing AI tools to standardize and enhance pathology assessments in clinical trials. Current scoring systems for MASH are subjective, with high variability among pathologists, which can lead to inaccurate trial outcomes and potential drug failures.<br /><br />Dr. Wack presents AIM-NASH, an AI-assisted tool validated with over 5,900 biopsies and qualified by the European Medicines Agency (EMA) as the first AI pathology tool enabling single pathologist reads to replace traditional multi-reader consensus, improving scoring accuracy and reproducibility. This tool better detects clinically meaningful changes over time and has been shown to reduce variability and increase trial power, demonstrated by retrospective analyses of trial data where AIM-NASH identified drug effects missed by manual reads.<br /><br />Beyond AIM-NASH, PATH AI is developing AIM-NASH+, providing sensitive quantitative continuous scores within ordinal bins, and Liver Explorer, an advanced tool analyzing cellular and spatial features from biopsies to identify new biomarkers and mechanisms of action. These innovations support precision medicine approaches in MASH and promise to improve therapeutic evaluation and biomarker discovery, with availability for research, collaborations, and regulatory-accepted use now.

Keywords

AI-powered digital pathology

Metabolic-associated steatohepatitis (MASH)

PATH AI

AIM-NASH

European Medicines Agency (EMA) qualification

Clinical trial scoring variability

Precision medicine in liver disease

Biomarker discovery